Published in Biochem Biophys Res Commun on October 23, 2013
Aspirin-triggered 15-epi-lipoxin A₄ signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation. Int J Cardiol (2014) 0.81
Effects of BM-573 on Endothelial Dependent Relaxation and Increased Blood Pressure at Early Stages of Atherosclerosis. PLoS One (2016) 0.76
Local Inhibition of Macrophage and Smooth Muscle Cell Proliferation to Suppress Plaque Progression. Methodist Debakey Cardiovasc J (2016) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol (2007) 3.02
Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. Cancer Res (2011) 2.96
Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost (2012) 2.24
Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem (2003) 2.00
Upregulation of the 5-lipoxygenase pathway in human aortic valves correlates with severity of stenosis and leads to leukotriene-induced effects on valvular myofibroblasts. Circulation (2011) 1.78
CoCl2, a chemical inducer of hypoxia-inducible factor-1, and hypoxia reduce apoptotic cell death in hepatoma cell line HepG2. Ann N Y Acad Sci (2002) 1.69
Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res (2006) 1.62
Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem (2008) 1.60
Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Mol Cell Biol (2007) 1.54
Autophagy as a mediator of chemotherapy-induced cell death in cancer. Biochem Pharmacol (2011) 1.53
Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS One (2012) 1.53
Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol (2013) 1.50
Is HIF-1alpha a pro- or an anti-apoptotic protein? Biochem Pharmacol (2002) 1.50
Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood (2002) 1.33
Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J Biol Chem (2004) 1.31
Anticonvulsant sulfonamides/sulfamates/sulfamides with carbonic anhydrase inhibitory activity: drug design and mechanism of action. Curr Pharm Des (2008) 1.29
Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci (2006) 1.27
Activation of the oxidative stress pathway by HIV-1 Vpr leads to induction of hypoxia-inducible factor 1alpha expression. J Biol Chem (2009) 1.21
Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res (2012) 1.21
Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol (2012) 1.20
Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation. Radiother Oncol (2011) 1.15
Hypoxia and CoCl2 protect HepG2 cells against serum deprivation- and t-BHP-induced apoptosis: a possible anti-apoptotic role for HIF-1. Exp Cell Res (2004) 1.13
Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol Cancer (2010) 1.12
Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth. Biochim Biophys Acta (2008) 1.11
Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost (2013) 1.02
Role of ERK and calcium in the hypoxia-induced activation of HIF-1. J Cell Physiol (2003) 1.02
Hypoxia induces protection against etoposide-induced apoptosis: molecular profiling of changes in gene expression and transcription factor activity. Mol Cancer (2008) 1.01
Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost (2013) 1.00
Dual effect of echinomycin on hypoxia-inducible factor-1 activity under normoxic and hypoxic conditions. FEBS J (2007) 0.99
Solid lipid microparticles as a sustained release system for pulmonary drug delivery. Eur J Pharm Biopharm (2006) 0.98
Role for casein kinase 2 in the regulation of HIF-1 activity. Int J Cancer (2005) 0.97
Hypoxia protects HepG2 cells against etoposide-induced apoptosis via a HIF-1-independent pathway. Exp Cell Res (2006) 0.97
TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells. BMC Cancer (2012) 0.96
Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J Exp Med (2009) 0.96
Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscler Thromb Vasc Biol (2009) 0.96
Leukotrienes and atherosclerosis. Curr Drug Targets (2010) 0.95
The role of hypoxia-inducible factor 1α in determining the properties of castrate-resistant prostate cancers. PLoS One (2013) 0.94
Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines. Mol Cancer (2007) 0.94
Site-directed mutagenesis studies of the hypoxia-inducible factor-1alpha DNA-binding domain. Biochim Biophys Acta (2002) 0.94
Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke. Med Res Rev (2012) 0.94
Vascular biology of eicosanoids and atherogenesis. Expert Rev Cardiovasc Ther (2009) 0.93
Meta-analysis of archived DNA microarrays identifies genes regulated by hypoxia and involved in a metastatic phenotype in cancer cells. BMC Cancer (2010) 0.93
Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia. J Allergy Clin Immunol (2009) 0.93
Effects of endotoxic shock on right ventricular systolic function and mechanical efficiency. Cardiovasc Res (2003) 0.92
Hypoxia-induced decrease in p53 protein level and increase in c-jun DNA binding activity results in cancer cell resistance to etoposide. Neoplasia (2009) 0.91
Effects of leaf extracts from Croton zambesicus Müell. Arg. on hemostasis. J Ethnopharmacol (2010) 0.91
Kinases as upstream regulators of the HIF system: their emerging potential as anti-cancer drug targets. Curr Pharm Des (2009) 0.91
The role of matrix metalloproteinases in atherothrombosis. Curr Atheroscler Rep (2011) 0.90
Anti-cancer activities of pH- or heat-modified pectin. Front Pharmacol (2013) 0.90
Casein kinase 2 inhibition decreases hypoxia-inducible factor-1 activity under hypoxia through elevated p53 protein level. J Cell Sci (2006) 0.89
Prostanoids as pharmacological targets in COPD and asthma. Eur J Pharmacol (2006) 0.89
New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr Med Chem (2004) 0.89
Intermittent hypoxia is an angiogenic inducer for endothelial cells: role of HIF-1. Angiogenesis (2009) 0.89
Inflammatory mediators in saliva associated with arterial stiffness and subclinical atherosclerosis. J Hypertens (2013) 0.88
Up-regulation of 94-kDa glucose-regulated protein by hypoxia-inducible factor-1 in human endothelial cells in response to hypoxia. FEBS Lett (2005) 0.88
Mitochondria permeability transition-dependent tert-butyl hydroperoxide-induced apoptosis in hepatoma HepG2 cells. Biochem Pharmacol (2004) 0.88
Intermittent hypoxia changes HIF-1alpha phosphorylation pattern in endothelial cells: unravelling of a new PKA-dependent regulation of HIF-1alpha. Biochim Biophys Acta (2007) 0.88
Thrombin generation assay and transmission electron microscopy: a useful combination to study tissue factor-bearing microvesicles. J Extracell Vesicles (2013) 0.88
Spectral and crystallographic study of pyridinic analogues of nimesulide: determination of the active form of methanesulfonamides as COX-2 selective inhibitors. J Med Chem (2002) 0.87
Synthesis and pharmacological evaluation of carboxycoumarins as a new antitumor treatment targeting lactate transport in cancer cells. Bioorg Med Chem (2013) 0.87
Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice. Contrast Media Mol Imaging (2013) 0.87
Large-pore membrane hemofiltration increases cytokine clearance and improves right ventricular-vascular coupling during endotoxic shock in pigs. Artif Organs (2006) 0.87
Low-LET proton irradiation of A549 non-small cell lung adenocarcinoma cells: dose response and RBE determination. Radiat Res (2013) 0.87
Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea. J Lipid Res (2012) 0.87
Hypoxia-induced modulation of apoptosis and BCL-2 family proteins in different cancer cell types. PLoS One (2012) 0.86
Carbonic anhydrase inhibitors as anticonvulsant agents. Curr Top Med Chem (2007) 0.86
Recent development in the field of dual COX / 5-LOX inhibitors. Mini Rev Med Chem (2004) 0.86
Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs? Pharmacol Res (2008) 0.86
High TMEM45A expression is correlated to epidermal keratinization. Exp Dermatol (2014) 0.85
Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT. J Clin Invest (2015) 0.85
ERK and calcium in activation of HIF-1. Ann N Y Acad Sci (2002) 0.85
Valvular osteoclasts in calcification and aortic valve stenosis severity. Int J Cardiol (2013) 0.85
The peroxynitrite donor 3-morpholinosydnonimine activates Nrf2 and the UPR leading to a cytoprotective response in endothelial cells. Cell Signal (2011) 0.85
Hybrid shell engineering of animal cells for immune protections and regulation of drug delivery: towards the design of "artificial organs". PLoS One (2011) 0.85
Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism. J Pharmacol Exp Ther (2004) 0.85
Thromboxane synthase expression and thromboxane A2 production in the atherosclerotic lesion. J Mol Med (Berl) (2010) 0.84
Implications of the molecular basis of prostacyclin biosynthesis and signaling in pharmaceutical designs. Curr Pharm Des (2006) 0.84
BNIP3 protects HepG2 cells against etoposide-induced cell death under hypoxia by an autophagy-independent pathway. Biochem Pharmacol (2010) 0.84
NOD2-mediated innate immune signaling regulates the eicosanoids in atherosclerosis. Arterioscler Thromb Vasc Biol (2013) 0.84
Leukotrienes as modifiers of preclinical atherosclerosis? ScientificWorldJournal (2012) 0.84
NDRG1 and CRK-I/II are regulators of endothelial cell migration under Intermittent Hypoxia. Angiogenesis (2009) 0.83
Characterisation of tissue factor-bearing extracellular vesicles with AFM: comparison of air-tapping-mode AFM and liquid Peak Force AFM. J Extracell Vesicles (2013) 0.83
Differential influence of anticancer treatments and angiogenesis on the seric titer of autoantibody used as tumor and metastasis biomarker. Neoplasia (2010) 0.83
Selective cyclooxygenase-2 inhibitors development in cardiovascular medicine. Circulation (2005) 0.82
Comparison of X-ray and alpha particle effects on a human cancer and endothelial cells: survival curves and gene expression profiles. Radiother Oncol (2013) 0.82
A p38(MAPK)/HIF-1 pathway initiated by UVB irradiation is required to induce Noxa and apoptosis of human keratinocytes. J Invest Dermatol (2010) 0.82
Intermittent hypoxia-activated cyclooxygenase pathway: role in atherosclerosis. Eur Respir J (2012) 0.82
Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation. Eur J Med Chem (2008) 0.81
Carbonic anhydrase inhibitors. Inhibition of isoforms I, II, IV, VA, VII, IX, and XIV with sulfonamides incorporating fructopyranose-thioureido tails. Bioorg Med Chem Lett (2007) 0.81
Progress in the field of GPIIb/IIIa antagonists. Curr Med Chem Cardiovasc Hematol Agents (2004) 0.81
Inhibition of nitric-oxide synthase enhances antigen-induced contractions and increases release of cysteinyl-leukotrienes in guinea pig lung parenchyma: nitric oxide as a protective factor. J Pharmacol Exp Ther (2005) 0.81
Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties. J Med Chem (2005) 0.81
Hypoxia regulates inflammatory gene expression in endothelial cells. Exp Cell Res (2008) 0.81
New trends in anti-malarial agents. Curr Med Chem (2002) 0.81
Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem (2008) 0.80
Mitochondrial respiratory chain as a new target for anti-ischemic molecules. Eur J Pharmacol (2002) 0.80
Urinary leukotriene E4 is associated with renal function but not with endothelial function in type 2 diabetes. Dis Markers (2013) 0.80
Carbonic anhydrase inhibitors: synthesis and topical intraocular pressure lowering effects of fluorine-containing inhibitors devoid of enhanced reactivity. J Med Chem (2004) 0.80